CONMED Corporation

CONMED's 23.6 P/E sits meaningfully above its electromedical peers, yet the stock trades nowhere near 52-week highs despite a neutral RSI of 46.1, suggesting the market hasn't fully repriced recent fundamentals or growth expectations. The 9.1% short interest is moderately elevated for a $1.1B medical device company, hinting at skepticism among bearish traders. This valuation premium combined with middling technical momentum creates an interesting tension—either the market is pricing in accelerating growth that hasn't materialized yet, or the stock is overextended relative to its operating trajectory. The lack of oversold conditions rules out an immediate reversal setup, but the valuation gap warrants scrutiny into whether near-term catalysts can justify the multiple.